Welcome to LookChem.com Sign In|Join Free
  • or
N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-propionamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

294850-87-6

Post Buying Request

294850-87-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

294850-87-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 294850-87-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,9,4,8,5 and 0 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 294850-87:
(8*2)+(7*9)+(6*4)+(5*8)+(4*5)+(3*0)+(2*8)+(1*7)=186
186 % 10 = 6
So 294850-87-6 is a valid CAS Registry Number.

294850-87-6Downstream Products

294850-87-6Relevant academic research and scientific papers

Discovery and characterization of the N-phenyl-N′-naphthylurea class of p38 kinase inhibitors

Cirillo, Pier F.,Hickey, Eugene R.,Moss, Neil,Breitfelder, Steffen,Betageri, Raj,Fadra, Tazmeen,Gaenzler, Faith,Gilmore, Thomas,Goldberg, Daniel R.,Kamhi, Victor,Kirrane, Thomas,Kroe, Rachel R.,Madwed, Jeffrey,Moriak, Monica,Netherton, Matthew,Pargellis, Christopher A.,Patel, Usha R.,Qian, Kevin C.,Sharma, Rajiv,Sun, Sanxing,Swinamer, Alan,Torcellini, Carol,Takahashi, Hidenori,Tsang, Michele,Xiong, Zhaoming

scheme or table, p. 2386 - 2391 (2009/12/07)

An effort aimed at exploring structural diversity in the N-pyrazole-N′-naphthylurea class of p38 kinase inhibitors led to the synthesis and characterization of N-phenyl-N′-naphthylureas. Examples of these compounds displayed excellent inhibition of TNF-α production in vitro, as well as efficacy in a mouse model of lipopolysaccharide induced endotoxemia. In addition, perspective is provided on the role of a sulfonamide functionality in defining inhibitor potency.

Method of treating mucus hypersecretion

-

, (2008/06/13)

The invention relates to the use of p38 kinase inhibitors for the preparation of a pharmaceutical composition suitable for inhalation for the treatment of mucus hypersecretion. Furthermore the invention is directed to pharmaceutical compositions suitable for inhalation comprising p38 kinase inhibitors and to methods for the preparation thereof.

Methods of treating cytokine mediated diseases

-

, (2008/06/13)

Disclosed are methods of treating acute and chronic inflammation in the lung caused by inhalation of smoke, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, sepsis, chronic obstructive pulmonary disease, traumatic arthritis, congestive heart failure and restenosis following percutaneous transluminal coronary angioplasty, known to be cytokine mediated, using aromatic heterocyclic compounds described in WO 00/55139.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 294850-87-6